Evidence map›Paper›PMID 40970984›Full record

ReviewJournal of cancer research and clinical oncology2025

Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia.

Xing Meng, Yue Zhang, Hong Xu, Yanyan Zhang, Hao He, Jianmin Ma, Xiaoyan Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xing Meng *Jiangxi Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Yue Zhang *Jiangxi Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Hong Xu *School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Yanyan ZhangJiangxi Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Hao HeJiangxi Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Jianmin MaJiangxi Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China.
Xiaoyan ZhangJiangxi Provincial Key Laboratory of Tumor Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi, China. zhangxiaoyan@ncu.edu.cn.

Funding

Jiangxi Province College Student Innovation and Entrepreneurship Training Program Project No. 202310403036Natural Science Foundation of Jiangxi Province No. 20242BAB25469the National Natural Science Foundation of China No. 82260034
6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a malignant clonal proliferative disease originating from hematopoietic stem cells. While treatment with tyrosine kinase inhibitors (TKIs) effectively eliminates the majority of leukemia cells in patients, residual leukemia cells can still be detected in those achieving deep molecular remission, ultimately leading to drug resistance or relapse. But the exact mechanism is unclear. In recent years, the immune microenvironment has been a hot research topic in hematologic malignancies. CML patients exhibit abnormalities in antitumor immunity. Myeloid-derived suppressor cells (MDSCs), which possess immune-suppressing functions, inhibit the proliferation and activation of CD4

Indexed as

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMyeloid-Derived Suppressor CellsAnimalsHumansTumor MicroenvironmentChronic myeloid leukemiaDrug resistanceImmunosuppressionMyeloid-derived suppressor cells

Identifiers

PMID40970984
PMCPMC12449292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.